Trial Profile

Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Doxorubicin (Primary) ; Sorafenib (Primary)
Indications Cholangiocarcinoma; Liver cancer
Focus Therapeutic Use
Acronyms Alliance

Most Recent Events

03 Aug 2022 Status changed from active, no longer recruiting to completed.
08 Jun 2021 Results of an analysis assessing genetic predictors of sorafenib-induced toxicities from two clinical studies: ALLIANCE and TARGET presented at the 57th Annual Meeting of the American Society of Clinical Oncology
17 Jan 2021 Results assesing radiomic signatures to predict survival in patients with advanced hepatocellular carcinoma by using data from this study presented at the 2021 Gastrointestinal Cancers Symposium.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com